Mark Diamond, CEO and Managing Director,and Cyprus Sia, Corporate Finance Analyst of Spark Plus talk about recent news.

Interview with Managing Director Mark Diamond following Investor Roadshow in Singapore

Mike Ham – Interview with CEO Mark Diamond 

Share Cafe Interview with Dr Charmaine Gittleson

Webinar Presentation by Mark Diamond – ShareCafe
Small Cap Hidden Gems Webinar

An interview with Duchenne Muscular Dystrophy expert Prof Thomas Voit – Shane Storey, Wilsons Equity Research

Morgans Desk Note 25 May 2020

Bioshares Report 25 May 2020

Under the Microscope – Morgans Senior Analyst Scott Power, spoke with Mark Diamond the CEO of Antisense Therapeutics (ANP) following the release of the positive Phase 2 Duchenne Muscular Dystrophy clinical trial results.

Bioshares Report – 18 December 2019

Stockhead TV – 90 seconds with Mark Diamond

Proactive Interview with CEO Mark Diamond: Antisense Therapeutics further develops therapeutic for Duchenne Muscular Dystrophy with ATL1102

Managing Director and CEO Mark Diamond provides an update on the company’s progress particularly around the Duchenne Muscular Dystrophy trial being undertaken in Australia.

ANP: Why partnering with big biotech has its benefits

Breakthrough Prize given to Antisense pioneer

ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment

Antisense Therapeutics could fill Duchenne Muscular Dystrophy treatment gap

Biotech Daily_Dr Boreham’s Crucible

Under the Microscope Antisense Therapeutics, Mark Diamond, Chief Executive Officer

Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech?